You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

  • Technology appraisal guidance
  • Reference number: TA583
  • Published:  05 June 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Declaration of interests
  2. Expected publication
  3. Final draft guidance
  4. Invitation to participate

History

A list of downloadable documents created during development.

Declaration of interests

  • Register of interests (PDF 152 KB)

    Published:
    17 February 2020

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 145 KB)

    Published:
    05 June 2019

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 241 KB)

    Published:
    26 April 2019
  • Committee papers (PDF 8.94 MB)

    Published:
    26 April 2019
  • Public committee slides ACM1 - clinical effectiveness (PDF 888 KB)

    Published:
    26 April 2019
  • Public committee slides ACM1 - cost effectiveness (PDF 335 KB)

    Published:
    26 April 2019
  • Public committee slides ACM2 (PDF 546 KB)

    Published:
    26 April 2019

Invitation to participate

  • Final scope (PDF 252 KB)

    Published:
    01 August 2018
  • Final matrix (PDF 264 KB)

    Published:
    01 August 2018
  • NICE's response to comments on the draft scope and provisional matrix (PDF 286 KB)

    Published:
    01 August 2018
Back to top